IPSEN (OTCMKTS:IPSEY) Shares Cross Above Two Hundred Day Moving Average – Should You Sell?

IPSEN (OTCMKTS:IPSEY) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $38.24 and traded as high as $44.0080. IPSEN shares last traded at $44.0080, with a volume of 245 shares.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on IPSEY. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research note on Tuesday, February 17th. UBS Group cut shares of IPSEN from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 8th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, IPSEN currently has an average rating of “Hold”.

IPSEN Trading Up 2.1%

The business has a 50-day moving average price of $43.58 and a two-hundred day moving average price of $38.24.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).